In addition, gefitinib sensitivity was also restored in non-small cell lung cancer cells when FGF2 and FGFR1 were inhibited via siRNA and treatment with a small molecule inhibitor, PD173074, suggesting FGFR activation as a potential mechanism of acquired resistance to EGFR-TKs [199]. This evidence concerns the gene FGF2 and non-small cell lung carcinoma.